Results 71 to 80 of about 4,861,637 (146)

Salvage Surgery Following Systemic Therapy in Initially Unresectable Non‐Small Cell Lung Cancer

Thoracic Cancer, Volume 16, Issue 24, December 2025.
Salvage pulmonary resection after systemic therapy for initially unresectable non‐small cell lung cancer achieved a high R0 rate with minimal morbidity and no perioperative mortality. Careful multidisciplinary selection facilitated a durable 5‐year survival rate of 75%.
Katsutoshi Seto, Yoshitsugu Horio, Katsuhiro Masago, Eiichi Sasaki, Hiroaki Kuroda, Yuta Matsubayashi, Hisanori Iwashimizu, Osamu Noritake, Keiyu Sato, Takuya Matsui, Soichiro Suzuki, Junichi Shimizu, Yutaka Fujiwara, Noriaki Sakakura   +13 more
wiley   +1 more source

Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy

Cancer Communications, Volume 45, Issue 11, Page 1513-1546, November 2025.
Abstract Since its discovery, the cyclic GMP‐AMP synthase (cGAS)‐stimulator of the interferon gene (STING) signaling pathway has been considered a pivotal component of innate immunity and a promising target for cancer immunotherapy. Beyond its canonical role in pathogen defense, accumulating evidence has demonstrated that the cGAS‐STING pathway ...
Yuheng Yan, Ximin Tan, Bin Song, Ming Yi, Qian Chu, Kongming Wu   +5 more
wiley   +1 more source

An easyguide to rare diseases in Ireland and consensus for action for government, the general public, media and political parties [PDF]

, 2020
The aims of this guide are to: • Explain what a rare disease is and how it is defined in health policy • Provide insights into living with a rare disease • Identify priorities patient advocacy groups would urge the Irish Government to include in the
IPPOSI, Health Research Charities Ireland, /, Rare Disease Ireland   +2 more
core  

Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study. [PDF]

Cancer Med, 2023
Hu C, Wu S, Deng R, Wu Y, Pan Y, Shu L, Wu F.   +6 more
europepmc   +1 more source

Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer

Current Oncology
We aimed to evaluate whether progression-directed radiation therapy (PDRT) can prolong the initiation of a subsequent systemic therapy regimen in a cohort of patients with oligoprogressive NSCLC.
Riccardo Ray Colciago, Chiara Chissotti, Federica Ferrario, Maria Belmonte, Giorgio Purrello, Valeria Faccenda, Denis Panizza, Stefania Canova, Gaia Passarella, Diego Luigi Cortinovis, Stefano Arcangeli   +10 more
doaj   +1 more source

Texas Preventable Disease News [PDF]

, 1988
Newsletter of the Texas Bureau of Disease Control and Epidemiology discussing the news, activities, and events of the organization and other information related to health in ...
Texas. Bureau of Disease Control and Epidemiology.
core   +2 more sources

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach

Exploration of Targeted Anti-tumor Therapy
Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advanced non-small cell lung cancer (NSCLC).
Francesca Di Pressa, Fabiana Perrone, Anna Benini, Frank Lohr, Marcello Tiseo, Alessio Bruni   +5 more
doaj   +1 more source

Treatment Approaches for Oligoprogressive Non-Small Cell Lung Cancer: A Review of Ablative Radiotherapy

Oligoprogressive disease refers to the setting of a prior or ongoing receipt of systemic therapy, with typically up to three metastatic areas having increased in size and/or avidity compared to the start of the systemic therapy.
Jyoti Malhotra, Ravi Salgia, William Gombrich, Yufei Liu, Terence Williams, Percy Lee, Nicholas Eustace, Adam Rock, Arya Amini, Ramya Muddasani   +9 more
core   +1 more source

Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases

Radiation
Background: Stereotactic body radiotherapy (SBRT) targeted at metastatic sites of disease progression is emerging as a potential therapeutic approach for managing oligoprogressive prostate cancer. However, a definitive benefit has yet to be demonstrated.
Emanuele Chioccola, Mara Caroprese, Christina A. Goodyear, Angela Barillaro, Caterina Oliviero, Stefania Clemente, Chiara Feoli, Luigi Formisano, Antonio Farella, Laura Cella, Manuel Conson, Roberto Pacelli   +11 more
doaj   +1 more source

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy

Frontiers in Oncology, 2019
Introduction: Therapy options for patients with oligoprogressive malignant pleural mesothelioma (MPM) are limited. Stereotactic Body Radiotherapy (SBRT) may be a promising therapeutic option, as it delivers a localized ablative dose of radiation and ...
Christina Schröder, Isabelle Opitz, Matthias Guckenberger, Rolf Stahel, Walter Weder, Robert Förster, Nicolaus Andratschke, Olivia Lauk   +7 more
doaj   +1 more source